Dosage and administration of Avmapki and Faczynja combination

The combination of Avmapki and Faczynja is a treatment option for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). This combination is particularly suitable for patients who have received prior systemic therapy. Before starting treatment, doctors need to select appropriate patients based on the presence of KRAS mutations in tumor specimens. It is worth mentioning that there are currently no FDA-approved tests for identifying KRAS mutations in LGSOC.

For the use ofAvmapki, the recommended dose is 3.2 mg, which is usually administered in four 0.8 mg capsules. Patients should take two doses in each 4-week cycle, on days 1 and 4 of the first 3 weeks, until disease progression or unacceptable toxicity. When taking, take orally with food and swallow the capsule whole without chewing, breaking or opening the capsule. If the patient misses a dose by more than 24 hours, the dose should be skipped and the next scheduled dose should be taken as prescribed. Importantly, patients should not take two doses at the same time to make up for a missed dose. In addition, if patients experience vomiting after taking Avmapki, they should not take additional doses and must take the next scheduled dose as prescribed.

The recommended dose of Faczynja is 200 mg taken orally twice daily for the first 3 weeks of each 4-week cycle. Patients should also take the tablet with food, swallow it whole, and avoid chewing, breaking or crushing the tablet. If the patient misses a dose by more than 6 hours, the dose should be skipped and the next scheduled dose should be taken as prescribed. Do not take two tablets at the same time to make up for it. If vomiting occurs after taking the drug, no additional dose should be taken but the normal dosing schedule should be followed.

During the treatment process, patients also need to undergo regular eye examinations. Regardless of baseline examination results, a comprehensive ophthalmic examination is recommended before the second cycle and every three cycles thereafter and as clinically indicated. In addition, to prevent skin reactions, the use of topical corticosteroids (for the face, scalp, neck, upper arms, and upper back), as well as systemic oral antibiotics, is recommended at the beginning and during the first two cycles of Avmapki-Faczynja combination to reduce the incidence of skin-related adverse reactions.

In terms of dose adjustment, due toAvmapki and Faczynja may cause a variety of adverse reactions, and the patient's dosage should be adjusted accordingly under the guidance of a physician. If the dose of Avmapki needs to be reduced, it can be adjusted to 2.4 mg twice weekly for the first 3 weeks of each 4-week cycle. The dose of Faczynja can be reduced to 200 mg orally once daily for the first 3 weeks of every 4-week cycle. For those patients who continue to be unable to tolerate treatment even after reducing their dose, their doctor may recommend permanent discontinuation of the Avmapki-Faczynja combination.

In short,The combined treatment of Avmapki and Faczynja requires strict compliance with dosage and medication methods, timely monitoring of adverse reactions during treatment, and appropriate adjustments according to the patient's specific situation. This comprehensive treatment strategy is designed to maximize treatment effectiveness while minimizing the patient's risk of side effects, ensuring that patients can maintain a good quality of life during treatment.

Reference materials:https://www.drugs.com/history/avmapki-faczynja-co-pack.html